These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 23962003

  • 1. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
    Lee JI, Eisenberg SP, Rosendahl MS, Chlipala EA, Brown JD, Doherty DH, Cox GN.
    J Interferon Cytokine Res; 2013 Dec; 33(12):769-77. PubMed ID: 23962003
    [Abstract] [Full Text] [Related]

  • 2. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.
    Bioconjug Chem; 2006 Dec; 17(3):618-30. PubMed ID: 16704199
    [Abstract] [Full Text] [Related]

  • 3. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 4. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005 Jan; 16(1):200-7. PubMed ID: 15656592
    [Abstract] [Full Text] [Related]

  • 5. Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon β-1b by site-specific PEGylation.
    Nairn NW, Shanebeck KD, Wang A, Graddis TJ, VanBrunt MP, Thornton KC, Grabstein K.
    Bioconjug Chem; 2012 Oct 17; 23(10):2087-97. PubMed ID: 22988919
    [Abstract] [Full Text] [Related]

  • 6. PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice.
    Fam CM, Eisenberg SP, Carlson SJ, Chlipala EA, Cox GN, Rosendahl MS.
    J Interferon Cytokine Res; 2014 Oct 17; 34(10):759-68. PubMed ID: 24841172
    [Abstract] [Full Text] [Related]

  • 7. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, Martin P.
    J Pharmacol Exp Ther; 2001 Jun 17; 297(3):1059-66. PubMed ID: 11356929
    [Abstract] [Full Text] [Related]

  • 8. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB.
    Bioconjug Chem; 2006 Jun 17; 17(1):179-88. PubMed ID: 16417267
    [Abstract] [Full Text] [Related]

  • 9. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.
    Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN.
    Exp Hematol; 2006 Jun 17; 34(6):697-704. PubMed ID: 16728273
    [Abstract] [Full Text] [Related]

  • 10. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
    Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF.
    Curr Pharm Des; 2002 Jun 17; 8(24):2139-57. PubMed ID: 12369859
    [Abstract] [Full Text] [Related]

  • 11. Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.
    Zheng Z, Okada R, Kobayashi H, Nagaya T, Wei J, Zhou Q, Lee F, Bera TK, Gao Y, Kuhlman W, Tai CH, Pastan I.
    Mol Cancer Ther; 2020 Mar 17; 19(3):812-821. PubMed ID: 31871266
    [Abstract] [Full Text] [Related]

  • 12. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.
    Int J Pharm; 2006 Feb 17; 309(1-2):87-93. PubMed ID: 16406701
    [Abstract] [Full Text] [Related]

  • 13. Novel pegylated interferon-β as strong suppressor of the malignant ascites in a peritoneal metastasis model of human cancer.
    Iwamura T, Narumi H, Suzuki T, Yanai H, Mori K, Yamashita K, Tsushima Y, Asano T, Izawa A, Momen S, Nishimura K, Tsuchiyama H, Uchida M, Yamashita Y, Okano K, Taniguchi T.
    Cancer Sci; 2017 Apr 17; 108(4):581-589. PubMed ID: 28129467
    [Abstract] [Full Text] [Related]

  • 14. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R.
    J Interferon Cytokine Res; 2001 Dec 17; 21(12):1103-15. PubMed ID: 11798469
    [Abstract] [Full Text] [Related]

  • 15. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
    Shahzadi SK, Qadir MA, Mahmood N, Ahmed M.
    Protein Pept Lett; 2020 Dec 17; 27(3):219-224. PubMed ID: 31612813
    [Abstract] [Full Text] [Related]

  • 16. Comparison of site-specific PEGylations of the N-terminus of interferon beta-1b: selectivity, efficiency, and in vivo/vitro activity.
    Zhou Z, Zhang J, Sun L, Ma G, Su Z.
    Bioconjug Chem; 2014 Jan 15; 25(1):138-46. PubMed ID: 24341722
    [Abstract] [Full Text] [Related]

  • 17. Recombinant protein hydrazides: application to site-specific protein PEGylation.
    Thom J, Anderson D, McGregor J, Cotton G.
    Bioconjug Chem; 2011 Jun 15; 22(6):1017-20. PubMed ID: 21618993
    [Abstract] [Full Text] [Related]

  • 18. [Site-specific monoPEGylated interferon alpha2a mediated by microbial transglutaminase].
    Hui X, Cao W, Zhang D, Ge W, Li S, Li Y.
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr 25; 36(4):750-762. PubMed ID: 32347069
    [Abstract] [Full Text] [Related]

  • 19. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
    Grace MJ, Lee S, Bradshaw S, Chapman J, Spond J, Cox S, Delorenzo M, Brassard D, Wylie D, Cannon-Carlson S, Cullen C, Indelicato S, Voloch M, Bordens R.
    J Biol Chem; 2005 Feb 25; 280(8):6327-36. PubMed ID: 15596441
    [Abstract] [Full Text] [Related]

  • 20. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
    Mcleod VM, Chan LJ, Ryan GM, Porter CJ, Kaminskas LM.
    J Pharm Sci; 2015 Apr 25; 104(4):1421-30. PubMed ID: 25631360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.